Is High LDL Cholesterol Genetic? What Research on Polygenic Scores, FH and Lifelong LDL Shows

Is High LDL Cholesterol Genetic? What Research on Polygenic Scores, FH and Lifelong LDL Shows

This article is for educational purposes only. It does not replace medical care, diagnosis, or genetic counseling from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Research shows that high LDL cholesterol is partly genetic. For most people, the genetic part comes from thousands of small gene effects, not one broken gene. In a large US sequencing study, only about 2 in 100 people with very high LDL carried a single-gene FH variant. A genetic report cannot tell you your LDL number. A simple blood test can, and that number guides care in US and Canadian guidelines.

What you’ll learn

• What a 23andMe “LDL Cholesterol” polygenic report measures, and what it does not
• How common, many-gene high LDL differs from familial hypercholesterolemia (FH)
• What twin, gene and drug studies say about lifelong LDL and heart risk
• Which tests, lifestyle steps and drugs matter, with US and Canadian approval status as of October 2026

What the 23andMe “LDL Cholesterol” polygenic report actually measures

LDL stands for low-density lipoprotein. Cholesterol travels in the blood inside these tiny particles. LDL is often called “bad” cholesterol. At high levels, it can build up as plaque in the arteries and reduce blood flow. The National Heart, Lung, and Blood Institute (NHLBI) says that both your genes and your habits play a major role.

Scientists found the genes behind LDL with genome-wide association studies, or GWAS. A GWAS scans the DNA of many thousands of people. It looks for common DNA spellings that show up more often in people with higher or lower LDL. A GWAS describes a population. It does not give any one person’s LDL or risk.

Three large studies built the map:

Study	Who took part	Main finding
Teslovich 2010, Nature	More than 100,000 people of European ancestry	95 gene regions linked to blood fats
Klarin 2018, Nature Genetics	297,626 US veterans, including 57,332 Black and 24,743 Hispanic participants	118 new gene regions, found together with an earlier consortium
Graham 2021, Nature	About 1.65 million people, including 350,000 of non-European ancestry	More diverse data made gene scores work better across groups

Each common variant has only a tiny effect. Most inherited LDL variation is spread across many gene regions, not one gene. A few of these genes are worth knowing by name:

• SORT1: the Teslovich team described it as a causal gene for LDL.
• HMGCR: this gene makes HMG-CoA reductase, the enzyme that statin drugs block.
• PCSK9: this gene makes the protein that PCSK9-inhibitor drugs target.

A polygenic score adds up the small effects of many variants into one number. It shows where a person sits compared with others in a research group. 23andMe lists its “LDL Cholesterol” report as a polygenic report built on 2,000+ variants. Think of it as many small dials, not one on-off switch.

23andMe also says its health reports are not meant to tell you about your current health. They are not meant for making medical decisions. So the report is not a diagnosis. Bring it to your primary care clinician as a talking point, not as a result.

Section recap: A polygenic LDL report sums thousands of tiny gene effects into a rough estimate. It does not measure your LDL and does not diagnose anything.

Polygenic high LDL vs familial hypercholesterolemia: two very different kinds of “genetic cholesterol”

Familial hypercholesterolemia, or FH, is a different condition. FH is caused by one rare harmful variant in a key gene such as LDLR, APOB or PCSK9. It is usually described as autosomal dominant. That means one changed copy, from either parent, is enough to raise LDL. Drug labels call this one-copy form heterozygous FH, or HeFH.

Polygenic high LDL works another way. It comes from many common variants that each nudge LDL up a little. The table shows the main contrasts.

Feature	Polygenic high LDL	Familial hypercholesterolemia (FH)
Cause	Thousands of common variants, each with a small effect	One rare variant in a gene such as LDLR, APOB or PCSK9
How often it explains very high LDL	Most cases of LDL at or above 190 mg/dL in one US study	About 2 in 100 cases in the same study
Heart risk at the same LDL	High	Higher, linked to more lifetime LDL exposure
What 23andMe tests	The “LDL Cholesterol” polygenic report	A separate limited report of 24 variants in LDLR and APOB

The key study is Khera and colleagues, 2016, in the Journal of the American College of Cardiology. The team sequenced FH genes in 26,025 people. Among 20,485 people without heart disease, 1,386 had LDL at or above 190 mg/dL (about 4.9 mmol/L). Only 24 of them, or 1.7%, carried an FH variant.

The study also reported odds ratios. An odds ratio compares the odds of a condition in one group with the odds in another group. The comparison group had LDL under 130 mg/dL and no FH variant:

• LDL at or above 190 mg/dL with no FH variant: about 6 times the odds of coronary artery disease
• LDL at or above 190 mg/dL with an FH variant: about 22 times the odds

These are relative figures. The study abstract does not give an absolute risk for each group.

A UK study by Talmud and colleagues in The Lancet adds a twist. About 60 in 100 UK patients with clinically diagnosed FH had no variant found in known FH genes. The team scored them with 12 common LDL-raising variants. Of 321 variant-negative patients, 167 (52%) scored in the top three tenths of population controls. In many of these patients, a polygenic cause may explain the high LDL.

Two cautions about 23andMe follow from this. First, the polygenic LDL report does not test for FH variants. Second, the separate FH report checks only 24 variants and does not test PCSK9. A “not detected” result does not rule out FH.

If your LDL is at or above 190 mg/dL, ask your clinician about an FH evaluation. The same applies if a parent or sibling had very high LDL or early heart disease. Read the FH guide for more detail.

Section recap: Most very high LDL is not single-gene FH, but FH carries extra risk at the same LDL level. A negative 23andMe FH result does not rule out FH, so ask a clinician when FH is suspected.

How much do genes move your LDL, and what does “higher than average” mean in real numbers?

Start with a number called heritability. Heritability is the share of the differences between people in a group that is linked to genes. It is a population figure. It is not the share of your own LDL that comes from your genes.

A US twin study followed 235 identical and 260 non-identical male twin pairs from about age 48 to 63. The heritability of LDL rose from 0.49 to 0.64 over time. In plain words, about half to two-thirds of the LDL differences between these men were linked to genes. The study included only men, mostly of one ancestry, so the figure may differ in other groups. Genes did not explain much of how LDL changed with age.

Next, why lifelong LDL matters. Mendelian randomization is a method that uses inherited variants as a natural experiment. People are born with variants that lower LDL for life, a bit like a coin toss at birth. Comparing them shows the effect of lifelong lower LDL.

Ference and colleagues pooled data from 312,321 people this way. Each 1 mmol/L (38.7 mg/dL) of lifelong lower LDL went with a 54.5% lower relative risk of coronary heart disease. Relative risk compares the risk in one group with the risk in another. The benefit was about three times larger per unit of LDL than statins started later in life. The abstract gives relative figures only, not absolute numbers.

A real-world gene study points the same way. In the ARIC study, 2.6% of 3,363 Black participants carried a PCSK9 variant. Their LDL was 28% lower on average. Their coronary heart disease risk over 15 years was 88% lower (hazard ratio 0.11). A hazard ratio is a type of relative risk over time. The 95% confidence interval was 0.02 to 0.81. A confidence interval is the range where the true value most likely sits. Among 9,524 white participants, a different PCSK9 variant went with 15% lower LDL and 47% lower risk.

Here are the numbers readers see on lab reports. Units differ: US labs use mg/dL, and Canadian labs use mmol/L.

Number	US (mg/dL)	Canada (mmol/L, approx.)	Source
Very high LDL, FH evaluation range	190 or higher	about 4.9
CCS statin threshold for likely genetic high LDL	about 193	5.0 or higher
CCS intermediate-risk statin threshold	about 135	3.5 or higher
2026 US goal, borderline or intermediate risk	under 100	about 2.6
2026 US goal, high risk	under 70	about 1.8

The conversions use 1 mmol/L = 38.7 mg/dL. They are rounded.

What about ancestry? Graham and colleagues showed that more diverse data improved how well scores work across groups. Accuracy is still uneven between ancestries. Klarin’s veteran study also found that some LDL variants differ by ancestry. A score built mostly on European data may fit others less well.

The most important point is simple. One blood test tells you your actual LDL. No genetic score can do that. Ask your clinician for a lipid panel if you have not had one recently.

Section recap: Twin studies show genes explain about half to two-thirds of LDL differences between people, not within one person. Lifelong lower LDL matters a lot, but only a blood test shows your real number.

Testing options: the lipid panel first, clinical genetic testing when FH is suspected, DTC reports for context

Think of testing as a ladder. The first step is the cheapest and most useful.

Step 1: the lipid panel (blood test). A lipid panel measures LDL and other blood fats. Fasting is often not required. The 2021 Canadian Cardiovascular Society (CCS) guideline recommends non-fasting tests for most adults. The NHLBI notes that a provider may ask you to fast 8 to 12 hours. Follow your clinician’s instruction.

When to test depends on age and country:

• Adults, US (NHLBI): every 5 years from ages 20 to 65. Men 45 to 65 and women 55 to 65 every 1 to 2 years. Every year after 65.
• Adults, Canada (CCS 2021): screening for men and women older than 40, or at any age with certain conditions.
• Children, ACC/AHA 2026 guideline: universal screening at ages 9 to 11, repeat at 19, then at least every 5 years.
• Children with close family history: testing from age 2 is reasonable when a close relative has FH, severe high cholesterol or early heart disease.
• Children, USPSTF 2023: an “I statement,” meaning the evidence is too limited to weigh benefits and harms of screening for those 20 or younger.

The US groups disagree on screening children. The ACC/AHA guideline and the NHLBI support universal screening at 9 to 11. The US Preventive Services Task Force (USPSTF) says the evidence is not enough to judge. Both positions stand. Parents can ask their child’s pediatrician which approach fits their family.

Step 2: lipoprotein(a), or Lp(a). Lp(a) is another blood fat particle. It is not usually part of a routine lipid panel. The 2026 ACC/AHA guideline says to measure it at least once in adulthood. The CCS also recommends one lifetime test. It is not part of the 23andMe LDL report.

Step 3: clinical genetic testing for FH. This looks for rare variants in genes such as LDLR, APOB and PCSK9. A clinician or genetic counselor orders it when FH signs are present. Writing-committee members said in an interview that the 2026 guideline recommends FH genetic testing in adults with LDL above 190 mg/dL and no obvious other cause. That point comes from the interview, not from the guideline text itself.

Step 4: direct-to-consumer (DTC) reports. These include the 23andMe LDL report. 23andMe filed for bankruptcy in March 2025. A nonprofit led by co-founder Anne Wojcicki, TTAM Research Institute, completed the purchase on 2025-07-14. The service still runs under the 23andMe name. Treat DTC results as background, not as a diagnosis.

Section recap: The lipid panel comes first, and FH genetic testing comes when FH is suspected. US groups disagree on child screening, so discuss it with a pediatrician.

Reading your result with a clinician: score, LDL level, and overall heart risk

Clinicians do not start from a genetic score. They start from your measured LDL and your overall heart risk. ASCVD means atherosclerotic cardiovascular disease, such as heart attack or stroke caused by plaque.

The 2026 ACC/AHA guideline replaced the 2018 cholesterol guideline. It is now the current US guidance. Here is what changed, based on published summaries of the guideline:

• It uses the PREVENT-ASCVD calculator for adults 30 to 79 without known ASCVD. This replaced the older Pooled Cohort Equations.
• PREVENT gives 10-year and 30-year risk. It does not use race.
• Risk-enhancing factors refine the estimate. These include early heart disease in the family and LDL that stays high.
• Lp(a), ApoB (a protein count of LDL-type particles) and a coronary artery calcium scan can help when the decision is unclear.
• It brings back LDL goals, such as under 100 mg/dL for borderline or intermediate risk.

In Canada, the CCS 2021 guideline uses the Framingham Risk Score. Statins are recommended for high risk (20% or more over 10 years). They are also recommended at intermediate risk (10% to 19.9%) when LDL is 3.5 mmol/L or higher. Family history of early heart disease, high Lp(a) and a calcium score above zero count as risk modifiers.

The USPSTF uses a simpler rule for adults 40 to 75. It gives a “B” grade for a statin when a person has a risk factor and a 10-year risk of 10% or more. It gives a “C” grade (offer selectively) at 7.5% to under 10%.

Where does a polygenic score fit? Neither USPSTF statement uses genetic scores to decide on statins. No polygenic score appears in the CCS pathway. Polygenic LDL scores are not part of the US (2026 ACC/AHA, as summarized) or Canadian treatment pathways.

Research still hints at a role. Natarajan and colleagues re-analyzed statin trials with a coronary polygenic score. In people at high genetic risk, statins cut relative risk by 46%, versus 26% in others. In absolute terms, about 4 in 100 versus about 1 in 100 people avoided an event. This used a coronary score, not the 23andMe LDL score. It is research context, not a care rule. For more on coronary scores, see the coronary artery disease guide.

Questions to bring to your appointment:

1. Ask for the current LDL value, in mg/dL or mmol/L.
2. Ask for the 10-year (and 30-year) heart risk, and which calculator was used.
3. Ask whether the family history counts as a risk-enhancing factor.
4. Ask whether a one-time Lp(a) test or a calcium scan makes sense.
5. Ask whether the LDL level or family history suggests an FH evaluation.

Section recap: Care decisions rest on measured LDL and overall risk, not on a polygenic score. Take a written question list to your clinician.

Lowering LDL when your genes push it up: lifestyle evidence and what it can and cannot do

Genes load the dice, but they do not decide the game. The CCS guideline calls health behaviour change the cornerstone of prevention. That includes regular exercise and a heart-healthy diet.

Khera and colleagues studied 55,685 people in four studies. They used a coronary polygenic score, not an LDL score. People in the top fifth of the score had a 91% higher relative risk of heart events than the bottom fifth. A favorable lifestyle meant at least three of these four habits:

• Not smoking
• Not having obesity
• Regular physical activity
• A healthy diet

Among people at high genetic risk, a favorable lifestyle went with 46% lower relative risk. In one cohort, 10-year heart events fell from about 11 in 100 to about 5 in 100. This was an observational study. It shows a link, not proof that changing habits caused the drop.

How far can diet move LDL itself? A review of controlled trials tested the “Portfolio” diet. It combines nuts, plant protein, sticky fiber and plant sterols. Adding it to a standard cholesterol-lowering diet cut LDL by about 17%, or about 28 mg/dL. The trials had 439 people with high blood fats. The evidence for LDL was rated high certainty.

Approach	Typical LDL effect in studies	Source
Portfolio diet added to a standard cholesterol diet	About 17% lower (about 28 mg/dL)
Bempedoic acid vs placebo at 6 months	About 29 mg/dL more lowering
Lifelong lower LDL from gene variants	About 55% lower relative heart risk per 38.7 mg/dL

Be honest about the limits. Diet can lower LDL in a real way. Some people with strong genetic loading will still need medicine. That is not a personal failure.

What about red yeast rice? The National Center for Complementary and Integrative Health (NCCIH) explains the risks. Monacolin K in red yeast rice is chemically the same as the drug lovastatin. Products with added or enhanced lovastatin cannot be sold as dietary supplements in the US. The amount of monacolin varied more than 60-fold between products. Some products contained citrinin, which can harm the kidneys. Supplements are not a swap for prescribed care. Talk to your clinician before trying any.

Section recap: Healthy habits are linked to much lower heart risk even with high genetic risk. Diet lowers LDL by a modest amount, and some people still need medicine.

The treatment landscape: statins, ezetimibe, PCSK9-targeted drugs and bempedoic acid

Human genetics pointed the way to several drugs. The HMGCR gene makes the enzyme that statins block. A natural LDL-lowering version of this gene went with lower coronary disease risk. PCSK9 variants that lower LDL for life went with much lower heart risk. That gene finding underpinned work on PCSK9-blocking drugs. Graham’s team also notes that lipid gene studies led to new drug targets.

All of these drugs need a prescription. None is approved to “treat” a polygenic score. The table shows FDA and Health Canada status as of October 2026.

Drug	FDA (US)	Health Canada
Statins, e.g. atorvastatin (LIPITOR)	Approved 1996-12-17. Generic forms exist	Authorized 1997-02-19
Ezetimibe (ZETIA in US, EZETROL in Canada)	Approved 2002-10-25	Authorized 2003-05-12
Evolocumab (REPATHA), injection	Approved 2015-08-27. Heart-event indication for adults at increased risk	Authorized 2015-09-10. Heart indication for adults with established ASCVD
Alirocumab (PRALUENT), injection	Approved 2015-07-24. Heart-event indication for adults at increased risk	Authorized 2016-04-11. Heart indication for adults with established heart disease. No child indication
Inclisiran (LEQVIO), injection	Approved 2021-12-22. LDL lowering only	Authorized 2021-07-26. Only with a maximally tolerated statin. Heart benefit not determined
Bempedoic acid (NEXLETOL in US, NILEMDO in Canada), tablet	Approved 2020-02-21. Heart-risk indication for adults unable to take recommended statins	Authorized 2025-11-14. Heart-risk use with a statin as tolerated
Enlicitide (LIPFENDRA), oral PCSK9 inhibitor	Approved 2026-07-15 for LDL lowering	No Health Canada record found as of 2026-10-20

A few details matter here. Evolocumab and alirocumab are antibodies that block PCSK9. Inclisiran is an injected siRNA, a genetic-silencing medicine that reduces PCSK9 production. In Canada, inclisiran is for adults already on the highest statin dose they can take. These adults must have HeFH, or non-familial high cholesterol with ASCVD. Neither the US nor Canadian label claims a proven heart-event benefit for inclisiran.

For bempedoic acid, the US and Canadian heart indications differ. The US wording covers adults at increased risk who cannot take recommended statin therapy. The Canadian wording is for adults at increased risk, used with a statin as tolerated. It allows use without a statin only for those unable to take statins at any dose. FDA approved efficacy updates in 2024 and 2025. Which one added the heart indication is inferred from dates, not confirmed.

The CLEAR Outcomes trial tested bempedoic acid. It enrolled 13,970 people who could not take statins. They were followed for a median of about 40 months. The drug lowered LDL by about 29 mg/dL more than placebo at 6 months. Major heart events happened in 11.7% on the drug versus 13.3% on placebo. That is about 12 versus 13 in 100 people. The drug had no significant effect on heart death, death from any cause, or stroke.

Some adverse events were reported more often with the drug in the trial:

• Gout: 3.1% vs 2.1%
• Gallstones: 2.2% vs 1.2%
• Small rises in creatinine, uric acid and liver enzymes

The trial was funded by the drug’s maker. Never start, stop or switch a cholesterol drug without your prescriber.

Section recap: Gene studies backed the statin target and pointed to PCSK9, and several drug classes now lower LDL. US and Canadian labels differ, so check the local label with your prescriber.

Family, children and insurance: what your result means for relatives and for GINA

Polygenic high LDL is shared in part within families, because relatives share many variants. Still, no fixed pattern predicts which relative will have high LDL. The practical step is a lipid panel for parents, siblings and children. Early heart disease in the family is itself a risk-enhancing factor in the 2026 guideline.

For children, the 2026 guideline supports screening at 9 to 11. Testing from age 2 is reasonable when a close relative has FH or early heart disease. The USPSTF still says the evidence is not enough for routine child screening. Talk with your child’s pediatrician.

Cascade testing means testing relatives step by step once a family variant is found. It applies when FH is confirmed by a genetic test. It is not used for a polygenic score.

Genetic counseling helps people understand genetic test results and what they mean for a family. Board-certified genetic counselors are certified by the American Board of Genetic Counseling. You can search for one through the National Society of Genetic Counselors directory at NSGC.org. A counselor can also help plan how to share results with siblings.

Insurance rules differ by country and by type of policy. In the US, the Genetic Information Nondiscrimination Act (GINA) of 2008 sets the main rules:

• Health insurers cannot use genetic information for eligibility, coverage, underwriting or premiums.
• Employers cannot use it for hiring, firing, pay or promotion.
• GINA does not apply to employers with fewer than 15 employees.
• GINA does not cover life, disability or long-term-care insurance.
• Some states, such as California, add broader protections.

In Canada, the Genetic Non-Discrimination Act of 2017 applies. No one can require a person to take or disclose a genetic test to get goods, services or a contract. That includes insurance contracts. The Supreme Court of Canada upheld the law on 2020-07-10.

There is a key difference here. A measured LDL value on a lab report is ordinary medical information, not a genetic test result. It is likely not shielded by GINA or the Canadian law in life-insurance underwriting. This reading comes from how the laws define genetic information. No regulator statement on LDL was found. If you are buying life insurance, ask a licensed advisor how your records will be used.

Try not to frame results as blame. Nobody chooses their variants. A calm family talk about blood tests helps more than a talk about fault.

For a related many-gene blood fat, see the triglycerides guide.

Section recap: Relatives benefit most from their own blood tests, and cascade testing applies only to confirmed FH. GINA protects health insurance and most jobs, but not life, disability or long-term-care insurance.

Frequently asked questions

Does a “higher than average” 23andMe LDL result mean a person will get heart disease?

No. The report estimates genetic likelihood only. 23andMe says it is not meant to tell about current health. Heart risk depends on measured LDL, blood pressure, smoking, diabetes and age. A lipid panel and a risk check with a clinician give a clearer picture.

Will a person’s children inherit high LDL?

Polygenic high LDL is partly shared in families, but not in a fixed pattern. Children can be screened by blood test at ages 9 to 11 under the ACC/AHA guideline. The USPSTF says evidence is not enough for routine child screening. A pediatrician can help decide.

Can a 23andMe cholesterol result affect health or life insurance?

In the US, GINA bars health insurers from using genetic information. GINA does not cover life, disability or long-term-care insurance. In Canada, the Genetic Non-Discrimination Act bars requiring genetic test results for insurance contracts. A measured LDL value is medical information and may be considered by life insurers.

Can an employer find out about a genetic result?

GINA bars employers with 15 or more employees from using genetic information in hiring, firing, pay or promotion. Smaller employers are not covered by GINA. Some states add broader protections.

Is a second opinion worth getting?

It can help when LDL is at or above 190 mg/dL, or when FH runs in the family. A lipid specialist or a genetic counselor can review the case. A negative 23andMe FH result does not rule out FH, so a clinical evaluation still matters.

Summary

• High LDL is partly genetic. For most people, thousands of small gene effects add up.
• Single-gene FH explained only about 2 in 100 cases of very high LDL in one large US study.
• Twin studies link about half to two-thirds of LDL differences between people to genes. This is a population figure, not a personal one.
• Lifelong lower LDL from gene variants went with much lower heart risk.
• A polygenic score is not part of US or Canadian treatment pathways. Measured LDL and overall risk guide care.
• Healthy habits are linked to lower risk even with high genetic risk. Diet lowers LDL by a modest amount.
• Several prescription drugs lower LDL. US and Canadian labels differ.
• GINA covers health insurance and most jobs, but not life insurance.

The next step is simple. Book a lipid panel and bring this article’s questions to your clinician or a genetic counselor.

For related topics, see the Metabolic and Hematologic Genetic Diseases category.

This article is for educational purposes only. It does not replace medical care, diagnosis, or genetic counseling from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. Teslovich TM, Musunuru K, Smith AV, et al. (2010) Nature 466(7307):707-713. Biological, clinical and population relevance of 95 loci for blood lipids. https://pubmed.ncbi.nlm.nih.gov/20686565/
2. Klarin D, Damrauer SM, Cho K, et al. (2018) Nature Genetics 50(11):1514-1523. Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. https://pubmed.ncbi.nlm.nih.gov/30275531/
3. Graham SE, Clarke SL, Wu KH, et al. (2021) Nature 600(7890):675-679. The power of genetic diversity in genome-wide association studies of lipids. https://pubmed.ncbi.nlm.nih.gov/34887591/
4. Goode EL, et al. (2007) Twin Research and Human Genetics. Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. https://pubmed.ncbi.nlm.nih.gov/17903110/
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. (2006) New England Journal of Medicine 354(12):1264-1272. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. https://pubmed.ncbi.nlm.nih.gov/16554528/
6. Ference BA, Yoo W, Alesh I, et al. (2012) Journal of the American College of Cardiology 60(25):2631-2639. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. https://pubmed.ncbi.nlm.nih.gov/23083789/
7. Khera AV, Won HH, Peloso GM, et al. (2016) Journal of the American College of Cardiology 67(22):2578-2589. Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. https://pubmed.ncbi.nlm.nih.gov/27050191/
8. Talmud PJ, Shah S, Whittall R, et al. (2013) The Lancet 381(9874):1293-1301. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. https://pubmed.ncbi.nlm.nih.gov/23433573/
9. Khera AV, et al. (2016) New England Journal of Medicine. Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. https://pubmed.ncbi.nlm.nih.gov/27959714/
10. Natarajan P, et al. (2017) Circulation. Polygenic Risk Score Identifies Subgroup With Higher Burden of Atherosclerosis and Greater Relative Benefit From Statin Therapy in the Primary Prevention Setting. https://pubmed.ncbi.nlm.nih.gov/28223407/
11. Nissen SE, Lincoff AM, Brennan D, et al.; CLEAR Outcomes Investigators (2023) New England Journal of Medicine 388(15):1353-1364. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. https://pubmed.ncbi.nlm.nih.gov/36876740/ (regulatory status: openFDA NDA211616; Health Canada DPD/NOC, NILEMDO DIN 02562782)
12. US FDA (openFDA Drugs@FDA and labels) and Health Canada (Drug Product Database, Notice of Compliance database, product monographs), accessed 2026-10-20. Approval status and labeled indications of LDL-lowering drugs. https://api.fda.gov/drug/drugsfda.json ; https://health-products.canada.ca/dpd-bdpp/ ; https://health-products.canada.ca/noc-ac/
13. Blumenthal RS, et al. (2026) Circulation / Journal of the American College of Cardiology. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. https://pubmed.ncbi.nlm.nih.gov/41824552/
14. US Preventive Services Task Force (2022, 2023) JAMA. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults; Screening for Lipid Disorders in Children and Adolescents. https://pubmed.ncbi.nlm.nih.gov/35997723/ ; https://pubmed.ncbi.nlm.nih.gov/37462699/
15. Pearson GJ, Thanassoulis G, Anderson TJ, et al. (2021) Canadian Journal of Cardiology 37(8):1129-1150. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. https://pubmed.ncbi.nlm.nih.gov/33781847/ ; https://ccs.ca/guideline/2021-lipids/
16. National Heart, Lung, and Blood Institute (NIH). Blood Cholesterol: Diagnosis (last updated 2024-04). https://www.nhlbi.nih.gov/health/blood-cholesterol/diagnosis
17. National Center for Complementary and Integrative Health (NIH). Red Yeast Rice: What You Need To Know (last updated 2022-11). https://www.nccih.nih.gov/health/red-yeast-rice
18. Chiavaroli L, et al. (2018) Progress in Cardiovascular Diseases. Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. https://pubmed.ncbi.nlm.nih.gov/29807048/
19. National Human Genome Research Institute (NIH), Genetic Discrimination; Genetic Non-Discrimination Act (S.C. 2017, c. 3); Reference re Genetic Non-Discrimination Act, 2020 SCC 17. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination ; https://laws-lois.justice.gc.ca/eng/acts/G-2.5/ ; https://scc-csc.ca/judgments-jugements/cb/2020/38478/
20. 23andMe. Genetic reports for clinicians: Health Predispositions (accessed 2026-10-20). https://www.23andme.org/clinicians/genetic-reports/health-predispositions/

---

Last updated: 2026-10-20

Author: Yu Mizuno (Editor-in-Chief, non-physician), GeneLumen editorial team. This article brings together 20 published sources. By tier, 15 are tier 1, 4 are tier 2 and 1 is tier 4. They include NIH sources (NHLBI, NCCIH and NHGRI), FDA and Health Canada drug records, and peer-reviewed studies indexed in PubMed. They also include ACC/AHA, USPSTF and Canadian Cardiovascular Society guidelines.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada).

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-metabolic-hematologic-genetic/high-ldl-cholesterol-polygenic-risk-ja